Table 3 Clinical and biochemical characteristics of the COVID-19 study cohort in the recovery phase of infection
From: Immunoglobulins in COVID-19 pneumonia: from the acute phase to the recovery phase
Variables | No Pneumoniaa (WHO 1) (n = 24) | Pneumoniab (WHO 2–7) (n = 228) | P-valuec |
|---|---|---|---|
Male | 12 (50) | 141 (61.8) | 0.259 |
Age, years | 54 (40.7–62.5) | 59 (50–68) | 0.025 |
Hematological parameters | |||
Leukocytes (×10E9/L) | 5.9 (4.8–6.5) | 5.7 (4.7–7.3) | 0.882 |
Red blood cell count (×10E9/L) | 4.6 (4–5.1) | 4.5 (4.2–4.8) | 0.395 |
Hemoglobin (g/dL) | 13.7 (12.2–14.8) | 13.2 (12.2–14.3) | 0.284 |
Hematocrit (%) | 42.5 (38.1–46) | 41.3 (37.8–44) | 0.218 |
Platelet count (×10E9/L) | 237.5 (184.2–284.2) | 228.5 (189–283) | 0.892 |
Neutrophils (%) | 56.2 (50–59) | 54.5 (47.8–61.1) | 0.896 |
Lymphocytes (%) | 33.7 (27.5–39.3) | 31.5 (26–37.8) | 0.309 |
Total lymphocytes | 1855 (1655–2517.5) | 1815 (1440–2292.5) | 0.193 |
Monocytes (%) | 8.3 (7.2–9.7) | 8.8 (7.4–10.2) | 0.411 |
Inflammatory markers | |||
d-Dimer (mg/L) | 418.5 (297–696.7) | 426 (331–686) | 0.459 |
Fibrinogen (g/L) | 426 (352.7–462.5) | 505.5 (426.7–592) | < 0.001 |
Interleukin 6 (pg/mL)d | 2.7 (0.5–2.8) | 2.2 (0.6–4) | 0.770 |
Ferritin (ng/mL) | 129 (68–292.5) | 180 (94–340) | 0.185 |
C Reactive Protein (mg/L) | 0.2 (0–0.4) | 0 (0–0.7) | 0.831 |
Biochemical markers | |||
Glucose (mg/dL) | 93.5 (85.5–107.5) | 98.5 (89–114) | 0.250 |
Urea (mg/dL) | 36 (27.7–47) | 36 (29–44) | 0.711 |
Creatinine (mg/dL) | 0.87 (0.8–0.9) | 0.8 (0.7–1) | 0.474 |
Aspartate aminotransferase (AST) (U/L) | 22 (19–27.2) | 23 (18–28) | 0.782 |
Alanine aminotransferase (ALT) (U/L) | 25 (19.7–34.2) | 30 (21–46) | 0.181 |
Lactate dehydrogenase (LDH) (U/L) | 193 (170–210) | 197 (175–221) | 0.333 |